On the other hand, increase in LCFA‐Cer (16:0) and decreases in VLCFA‐Cer (22:0, 24:0) in obese subjects, resulting from imbalance of CerS2/6 expression and inhibition of β‐oxidation, were reported to correlate to progression of metabolic disorders (Raichur et al, 2014; Turpin et al, 2014). Here, CERS2 is linked to metabolic disease.